CORONA Remedies Limited has informed the Exchange regarding a press release dated May 11, 2026, titled "Press Release on Financial Results of the Company for Q4FY26 and year ended March 31, 2026".
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.0 pts less than Nifty Microcap 250 and 4.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
CORONA Remedies reported strong Q4FY26 and FY26 results with revenue growing 20.2% YoY in Q4 to ₹353.1 Cr and 17.3% YoY in FY26 to ₹1,403.2 Cr. PAT surged 43.7% in Q4 to ₹45.3 Cr and 33.4% in FY26 to ₹199.4 Cr, with margins expanding by 210 bps and 172 bps respectively. The company acquired WOKADINE (entry into ₹648 Cr Povidone Iodine market), relaunched key brands, and improved its industry ranking to 27th in India. Note: PAT includes a one-time statutory impact of New Labor Code of ₹14.3 Crores (post-tax) in FY26. EBITDA grew 22.3% for FY26 to ₹293.4 Cr with margin expansion of 85 bps.
The company delivered robust double-digit revenue and profit growth with margin expansion, indicating strong operational efficiency and brand strength. The acquisition and relaunched brands position the company well for continued growth. However, shareholders should note the one-time labor code impact inflating FY26 PAT figures.